首页> 外文OA文献 >Lu-177 labelled Rituximab - new approach to have suitable radiopharmaceutical
【2h】

Lu-177 labelled Rituximab - new approach to have suitable radiopharmaceutical

机译:Lu-177标记为利妥昔单抗 - 一种获得合适放射性药物的新方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The purpose of this investigation was to introduce a technology for the production of ready-to-use cold kit formulations for the labelling of conjugated DOTA-Rituximab with Lu-177, and to standardize the methods for synthesis and conjugation. In a parallel study, the biological properties and pharmacokinetic behaviors of radiolabelled DOTA-Rituximab were investigated to compare and determine their toxicities and therapeutic efficacies using model systems comprising both isolated cell cultures and laboratory animals.udDTPA- or DOTA- chelated antibodies have been proved to be effective in radioimmunotherapy of cancer after radiolabelling with beta-emmiting radionuclides. The standardization of methods for conjugation of suitable chelators to monoclonal antibodies and the further pharmaceutical development of these conjugates were planned within the framework of an IAEA coordinated research project aimed at developing radiopharmaceuticals labelled with Lu-177.udTherefore, our study was focused on the development of a freeze-dried kit formulation based on DOTA-antiCD20 Rituximab for Lu-177 labeling, as a potential radiopharmaceutical for radionuclide therapy.udFor this reason, the first part of our work was devoted to establish an efficient freeze-drying procedure for developing a final kit formulation for simple antibody labeling. The procedure for freeze-drying should provide a stable ready-to-use kit formulation, having the same labeling efficiency as established for the freshly prepared laboratory preparation. The freeze-dried formulation should preserve the same immunoreactivity of the antibody before and after conjugation as already observed for the liquid formulation. For this reason, we focused our study on the evaluation of the most important steps required to set up a suitable freeze-drying protocol and, in particular, to estimate the optimal time for lyophilization of the monoclonal antibody during each phase of the process, e.g. (a)pre-freezing, (b) primary drying, and (c) secondary drying. ud
机译:这项研究的目的是介绍一种生产用于用Lu-177标记共轭DOTA-利妥昔单抗的即用型冷试剂盒制剂的技术,并使合成和结合的方法标准化。在一项平行研究中,使用包含分离的细胞培养物和实验室动物的模型系统研究了放射性标记的DOTA-利妥昔单抗的生物学特性和药代动力学行为,以比较和确定其毒性和治疗效果。已经证明了udDTPA或DOTA螯合的抗体在使用发射β的放射性核素进行放射性标记后,对癌症的放射免疫治疗有效。在国际原子能机构旨在研究用Lu-177标记的放射性药物的协调研究项目的框架内,计划了将合适的螯合剂与单克隆抗体偶联的方法的标准化以及这些偶联物的进一步药物开发。 ud因此,我们的研究重点是开发基于Luta-177标记的DOTA-antiCD20利妥昔单抗的冻干试剂盒制剂,作为放射性核素治疗的潜在放射性药物。 ud因为这个原因,我们第一部分的工作致力于建立一种有效的冻干程序,用于开发用于简单抗体标记的最终试剂盒配方。冷冻干燥程序应提供稳定的即用型试剂盒配方,其标记效率应与为新鲜制备的实验室制剂所确定的相同。冷冻干燥的制剂在缀合之前和之后应保持与液体制剂相同的抗体免疫反应性。出于这个原因,我们将研究重点放在评估建立合适的冻干方案所需的最重要步骤上,尤其是评估在过程的每个阶段(例如,冷冻干燥)中单克隆抗体冻干的最佳时间。 (a)预冷冻,(b)一次干燥和(c)二次干燥。 ud

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号